Announcing FierceBiomarkers, a channel of FierceBiotech Research

Biomarkers have become one of the most important tools in drug developers' research kits. And the team here at FierceMarkets is adding a news channel--FierceBiomarkers--as a twice monthly supplement to FierceBiotech Research to track developments in the field.

Sign-up for the FierceBiomarkers channel here.

Virtually everyone in the industry understands that biopharma companies are focused on a new generation of personalized therapies that can address serious unmet medical needs. Biomarkers can be used to better target diseases, as well as help diagnose ailments, playing a key role at all stages of the development process. And that role will only grow in importance in years to come.

Our new FierceBiomarkers report, launching June 30 and delivered every other Wednesday, will track the biomarker news and trends that have a direct impact on developers around the world who turn to us for our trademark analyses of important industry events.

FierceBiomarkers is the ninth news operation for the life sciences division of FierceMarkets, reflecting our commitment to providing the best, most comprehensive coverage of the global biotech business now available. I hope you sign up for it. And if you have any suggestions on stories we should cover, please let me know. - John Carroll (twitter | e-mail)


Publisher's Note: FierceBiomarkers--our first dedicated FierceBiotech Research channel--is brought to you exclusively by Quest Diagnostics Clinical Trials. Due to their support, John Carroll and the Fierce Life Sciences editorial team will be providing the kind of Fierce news coverage in biomarkers our readers have come to expect. - Arsalan Arif (twitter | e-mail)

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.